On the applicability of [18F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapy

In recent years extra-corporal application of Boron Neutron Capture Therapy (BNCT) was evaluated for liver primary tumors or liver metastases. A prerequisite for such a high-risk procedure is proof of preferential delivery and high uptake of a 10B-pharmaceutical in liver malignancies. In this work we evaluated in a preclinical tumor model if [18F]FBPA tissue distribution measured with PET is able to predict the tissue distribution of [10B]L-BPA.

Source: Nuclear Medicine and Biology - August 28, 2016 Category: Nuclear Medicine Authors: Catrin Grunewald, Michael Sauberer, Thomas Filip, Thomas Wanek, Johann Stanek, Severin Mairinger, Sofia Rollet, Petra Kudejova, Oliver Langer, Christian Sch ütz, Matthias Blaickner, Claudia Kuntner Source Type: research